New pill takes on rare, stubborn lymphoma
Disease control
Recruiting now
This early-phase trial is testing an oral drug called VK-2019 in 30 adults with a type of lymphoma (DLBCL) that is linked to the Epstein-Barr virus and has not responded to at least two prior treatments. Participants take the drug daily in 28-day cycles at one of three dose level…
Phase: PHASE1 • Sponsor: Pierluigi Porcu • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC